Clinical Trial Update: Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for certolizumab pegol in active axial spondyloarthritis completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Axial Spondyloarthritis
• Spondyloarthropathies

Drugs mentioned

• Certolizumab pegol (certolizumab pegol)

Snippet

Sponsor: UCB BIOSCIENCES GmbH | Conditions: Spondyloarthropathies | Phase 3 | Status: COMPLETED | Results posted: 2013-12-25